eMedicine Specialties > Rheumatology > Spondyloarthropathies
Psoriatic Arthritis: Differential Diagnoses & Workup
Updated: Apr 29, 2009
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
- Multimedia
Differential Diagnoses
Gout
Osteoarthritis
Reactive Arthritis
Rheumatoid Arthritis
Septic Arthritis
Other Problems to Be Considered
Psoriasiform skin lesions may be observed in association with Reiter disease, inflammatory bowel disease, and the syndrome of inappropriate secretion of diuretic hormone.
Workup
Laboratory Studies
- No specific diagnostic tests are available for psoriatic arthritis. Diagnosis of the disease is made based on clinical and radiologic criteria in a patient with psoriasis.
- The most characteristic laboratory abnormalities in patients with psoriatic arthritis are elevations of the erythrocyte sedimentation rate (ESR) and C-reactive protein level. The results from these laboratory tests help track the activity of the disease by measuring inflammation. An elevated ESR is usually found in approximately 40% of patients with psoriatic arthritis.
- Patients with psoriatic arthritis are typically seronegative for RF, although RF is detected in 5-9% of patients. RF testing is usually associated with a high false-positive rate; thus, RF-positive and RF-negative patients should undergo the same treatment.
- Antinuclear antibody titers in persons with psoriatic arthritis do not differ from those of age- and sex-matched control populations. In 10-20% of patients with generalized skin disease, the serum uric acid concentration may be increased and, on occasion, may predispose to acute gouty arthritis. Low levels of circulating immune complexes have been detected in 56% of patients with psoriatic arthritis but do not appear to parallel disease activity.
- The associations of psoriatic arthritis with HLA-B17, -Cw6, -DR4, and -DR7 are described in Genetics. Serum immunoglobulin A levels are increased in two thirds of patients with psoriatic arthritis and in one third of patients with psoriasis.
- Synovial fluid is inflammatory, with cell counts ranging from 5000-15,000/µL and with more than 50% of cells being polymorphonuclear leukocytes. Within the synovium, the infiltrate consists predominantly of T lymphocytes. Synovial fluid complement levels are either within reference ranges or increased, and glucose levels are within reference ranges.
Imaging Studies
- Radiological features have helped to distinguish psoriatic arthritis from other causes of polyarthritis. In general, the common subtypes of psoriatic arthritis, such as asymmetric oligoarthritis and symmetric polyarthritis, tend to result in only mild erosive disease. Early bony erosions occur at the cartilaginous edge, and, initially, cartilage is preserved, with maintenance of a normal joint space.
- Juxta-articular osteopenia, which is a hallmark of rheumatoid arthritis (RA), is minimal in persons with psoriatic arthritis. Asymmetric erosive changes in the small joints of the hands and feet are typical of psoriatic arthritis and have a predilection (in decreasing order) for DIP, proximal interphalangeal, metatarsophalangeal, and metacarpophalangeal joints.
- Erosive disease frequently occurs in patients with either DIP involvement or progressive deforming arthritis and may lead to subluxation and, less commonly, bony ankylosis of the joint. Erosion of the tuft of the distal phalanx, and even the metacarpals or metatarsals, can progress to complete dissolution of the bone. Although this form of acroosteolysis is not diagnostic, it is highly suggestive of psoriatic arthritis. The pencil-in-cup deformity observed in the hands and feet of patients with severe joint disease usually affects the DIP joints but also may involve the proximal interphalangeal joints.
- CT scanning of the sacroiliac joint may be a sensitive method of visualizing involvement in patients with spondylitis or sacroiliitis.
- Recent studies have indicated that MRI may be a sensitive method for demonstrating the typical enthesopathic pathology of psoriatic arthritis, particularly in the hands and feet.
Other Tests
- Traditional methods of monitoring patients with rheumatic conditions include clinical assessment for joint inflammation or damage and radiographic evaluations. The radiologic scoring methods for evaluating peripheral joints in persons with psoriatic arthritis were developed for patients with RA. A study validated the original Steinbrocker method, a modified Steinbrocker method, and the Larsen method for assessment of radiographs in patients with psoriatic arthritis. The latter 2 methods can now be used to assess disease progression in patients with psoriatic arthritis.
Histologic Findings
The histopathology of psoriatic synovitis is similar to that observed in other inflammatory arthritides, with a notable lack of intrasynovial immunoglobulin and RF production and a greater propensity for fibrous ankylosis, osseous resorption, and heterotopic bone formation.
More on Psoriatic Arthritis |
| Overview: Psoriatic Arthritis |
Differential Diagnoses & Workup: Psoriatic Arthritis |
| Treatment & Medication: Psoriatic Arthritis |
| Follow-up: Psoriatic Arthritis |
| Multimedia: Psoriatic Arthritis |
| References |
| Further Reading |
| « Previous Page | Next Page » |
References
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. Jul 26 2006;54(8):2665-2673. [Medline].
[Best Evidence] Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. Mar 2009;60(3):402-11. [Medline].
Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. Nov/2007;Ahead of print:[Medline].
Andrews BS, Lowe NJ. Therapy of psoriatic arthritis. In: Practical Psoriasis Therapy. 2nd ed. St. Louis, Mo: Mosby-Year Book; 1993:239-55.
Bruce I, Gladman DD. Psoriatic Arthritis: Recognition and Management. BioDrugs. 1998;9:271.
Calzavara-Pinton PG, Franceschini F, Manera C, Zane C, Prati E, Cretti L, et al. Antiperinuclear factor in psoriatic arthropathy. J Am Acad Dermatol. Jun 1999;40(6 Pt 1):910-3. [Medline].
Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin. Jan 2001;19(1):119-37, ix. [Medline].
Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. Dec 1996;39(12):2013-20. [Medline].
Cuellar ML, Silveira LH, Espinoza LR. Recent developments in psoriatic arthritis. Curr Opin Rheumatol. Jul 1994;6(4):378-84. [Medline].
Dougados M, Maetzel A, Mijiyawa M, Amor B. Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis. Aug 1992;51(8):955-8. [Medline].
Eastmond CJ. Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol. May 1994;8(2):263-76. [Medline].
Espinoza LR, van Solingen R, Cuellar ML, Angulo J. Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci. Oct 1998;316(4):271-6. [Medline].
Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440. [Medline].
Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol. Jun 1986;13(3):586-92. [Medline].
Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol. Mar 1999;60(3):259-61. [Medline].
Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol. Nov 1999;26(11):2409-13. [Medline].
Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. Jun 1998;41(6):1103-10. [Medline].
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med. Feb 1987;62(238):127-41. [Medline].
Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del Rio J, Rodriguez Perez A, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum. May 1999;42(5):1010-6. [Medline].
Goodfield M. Skin lesions in psoriasis. Baillieres Clin Rheumatol. May 1994;8(2):295-316. [Medline].
Griffiths CE. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol. Apr 1997;36(4):409-10. [Medline].
Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol. May 2000;42(5 Pt 1):835-7. [Medline].
Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. May 1995;22(5):894-8. [Medline].
Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. Oct 1997;109(4):562-5. [Medline].
Hohler T, Marker-Hermann E. Psoriatic arthritis: clinical aspects, genetics, and the role of T cells. Curr Opin Rheumatol. Jul 2001;13(4):273-9. [Medline].
Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. Apr 2009;60(4):976-86. [Medline].
Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. Apr 17 2001;134(8):695-706. [Medline].
Kurschat P, Rubbert A, Poswig A, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of psoriatic arthritis with etanercept. J Am Acad Dermatol. Jun 2001;44(6):1052. [Medline].
Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis. Feb 1981;40(1):66-9. [Medline].
Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. Nov 20 2003;349(21):2014-22. [Medline].
Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis?. Clin Invest Med. Apr 1995;18(2):139-43. [Medline].
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. Sep 1998;41(9):1552-63. [Medline].
Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol. Jan 2005;52(1):1-19. [Medline].
Mease P, Siegel E, Ruderman EM, et al. Etanercept (Enbrel) in patients with psoriatic arthritis and psoriasis: continued observations [abstract]. Ann Rheum Dis. 2003;62:(suppl 1).
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. Jul 29 2000;356(9227):385-90. [Medline].
Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. Apr 1999;140 Suppl 54:1-7. [Medline].
Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol. Aug 1990;29(4):280-3. [Medline].
Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. Oct 1998;25(10):1957-61. [Medline].
Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol. May 2001;28(5):1041-4. [Medline].
Roenigk HH, Maibach HI. Psoriatic arthritis. In: Psoriasis. 2nd ed. New York, NY: Marcel Dekkar; 1991:171-87.
Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's Textbook of Rheumatology. 6th ed. Philadelphia, Pa: WB Saunders; 2000.
Sakkas LI, Marchesoni A, Kerr LA, Ranza R, Colombo B, Welsh KI, et al. Immunoglobulin heavy chain gene polymorphisms in Italian patients with psoriasis and psoriatic arthritis. Br J Rheumatol. Dec 1991;30(6):449-50. [Medline].
Sontheimer RD, Provost TT, eds. Cutaneous Manifestations of Rheumatoid Diseases. ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1996:233-6.
Further Reading
For additional information, see Medscape’s Psoriasis Resource Center and Arthritis Resource Center.
Keywords
psoriatic arthritis, spondylitic psoriatic arthritis, rheumatoid psoriatic arthritis, psoriasis, arthritis, skin disease, bone disease, rheumatism, rheumatoid arthritis, psoriatic arthropathy, arthritis mutilans, arthropathia psoriatica, psoriatic spondylitis, asymmetrical seronegative oligoarticular arthritis, dactylitis, sausage digits, pencil-in-cup radiograph, opera-glass hand, asymmetrical oligoarticular arthritis, symmetrical polyarthritis, distal interphalangeal arthropathy, juvenile psoriatic arthritis, sacroiliitis


Differential Diagnoses & Workup: Psoriatic Arthritis